Detalles de la búsqueda
1.
Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study.
Blood
; 140(9): 1009-1019, 2022 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35544601
2.
Outcome of combined modality treatment in first-line for stage I(E) peripheral T-cell lymphoma; a nationwide population-based cohort study from the Netherlands.
Haematologica
; 109(4): 1163-1170, 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37794805
3.
A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma.
Hematol Oncol
; 41(1): 108-119, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36251503
4.
Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study.
Neuro Oncol
; 26(4): 724-734, 2024 04 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38037691
5.
Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOS.
Blood Adv
; 8(5): 1094-1104, 2024 Mar 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38191686
6.
Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry.
Blood Adv
; 2024 May 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38739705
7.
The course of self-perceived cognitive functioning among patients with lymphoma and the co-occurrence with fatigue and psychological distress.
J Cancer Surviv
; 2023 Sep 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-37755680
8.
Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities.
JCO Oncol Pract
; 19(3): e407-e416, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36508702
9.
Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities.
Cancers (Basel)
; 15(22)2023 Nov 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38001703
10.
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.
Blood Cancer J
; 13(1): 93, 2023 06 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-37336890
11.
The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands.
Cancers (Basel)
; 15(17)2023 Aug 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37686611
12.
In vitro-differentiated T/natural killer-cell progenitors derived from human CD34+ cells mature in the thymus.
Blood
; 115(2): 261-4, 2010 Jan 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-19828700
13.
Assessing long-term effects after stem cell transplantation: design of the MOSA study.
J Clin Epidemiol
; 148: 10-16, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35346784
14.
Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis.
Eur J Cancer
; 176: 100-109, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36208568
15.
Stage-specific trends in primary therapy and survival in follicular lymphoma: a nationwide population-based analysis in the Netherlands, 1989-2016.
Leukemia
; 35(6): 1683-1695, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33046819
16.
Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study.
Blood Adv
; 5(15): 2958-2964, 2021 08 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34338755
17.
The impact of prior malignancies on the development of second malignancies and survival in follicular lymphoma: A population-based study.
EJHaem
; 1(2): 489-497, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35844986
18.
Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS.
Blood Adv
; 4(18): 4267-4277, 2020 09 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-32915972
19.
Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapy.
Blood Adv
; 7(21): 6710-6716, 2023 11 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37639324
20.
R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma.
Blood Cancer J
; 12(9): 125, 2022 09 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36055987